8-K: CV Sciences Reports Q3 Revenue Decline Amid Regulatory Headwinds

CV Sciences, Inc. announced its third quarter 2025 financial results, reporting a 16% revenue decrease and a widened adjusted EBITDA loss, while facing new federal hemp industry restrictions.

Summary

• Revenue for the third quarter 2025 was $3.3 million, a 16% decrease from $3.9 million in the third quarter 2024, and a decrease from $3.6 million in the second quarter 2025.
• Gross margin improved to 48.5% for the third quarter 2025, up from 46.0% in the third quarter 2024, but down from 50.9% in the second quarter 2025.
• Adjusted EBITDA loss widened to $118,000 for the third quarter 2025, compared to a loss of $75,000 for the third quarter 2024, and a positive adjusted EBITDA of $59,000 for the second quarter 2025.
• The company reported a net loss of $382,000 for Q3 2025, an improvement from a net loss of $456,000 in Q3 2024.
• Cash balance stood at $0.4 million at quarter end, down from $0.5 million at the end of 2024.
• Operating loss remained consistent at $0.3 million for both the third quarter 2025 and 2024.
• Sales volume, measured by units sold, decreased by 16% compared to the third quarter 2024.
• New products launched since January 1, 2023, accounted for 39% of net revenue in Q3 2025, with 38 new products introduced during this period.
• The company launched 'Ignite,' a men's performance formula, expanding its +PlusCBD product offering.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to significant revenue decline, worsening adjusted EBITDA loss, and continued cash burn. While gross margins improved year-over-year and net loss narrowed, the core operational performance is weak. The regulatory headwind, though delayed, adds uncertainty. Strategic initiatives like new product launches and M&A focus provide some positive outlook, but current financial trends are concerning.

Positives

• Gross margin improved to 48.5% in Q3 2025 compared to 46.0% in Q3 2024, indicating better cost management relative to sales.
• Net loss decreased to $382,000 in Q3 2025 from $456,000 in Q3 2024, showing an improvement in overall profitability despite revenue decline.
• New product development is a significant revenue driver, with 39% of Q3 2025 net revenue coming from 38 new products launched since January 1, 2023.
• The company successfully launched 'Ignite,' a new men's performance formula, diversifying its product portfolio.
• Restrictive federal hemp legislation will not go into effect for a one-year period from November 13, 2025, providing a temporary reprieve and opportunity for industry lobbying.

Negatives

• Revenue decreased by 16% to $3.3 million in Q3 2025 from $3.9 million in Q3 2024, indicating a significant top-line decline.
• Adjusted EBITDA loss widened to $118,000 in Q3 2025 from $75,000 in Q3 2024, and shifted from a positive $59,000 in Q2 2025, reflecting deteriorating operational profitability.
• Cash balance declined to $0.4 million at quarter end from $0.5 million at the end of 2024, suggesting ongoing cash burn.
• Sales volume decreased by 16% in Q3 2025 compared to Q3 2024, driven by out-of-stock issues for key products and restrictive state regulations.
• Gross margin decreased from 50.9% in Q2 2025 to 48.5% in Q3 2025, indicating a sequential decline in product profitability.

Risks

• Restrictive regulations in certain states are impacting sales volume.
• New federal funding legislation includes restrictive language for the hemp industry, posing a future regulatory challenge, although its implementation is delayed for one year.
• Forward-looking statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict, potentially leading to actual outcomes differing materially from expectations.

Future Outlook

The company plans to focus on organic growth through new product development and strategic M&A opportunities to enhance top-line revenue and shareholder value. It aims to diversify its product portfolio through innovation and navigate the evolving regulatory landscape in the CBD category. Management is committed to building a more balanced portfolio that drives sustainable growth and profitability and will work with industry participants and Congress to shape a balanced regulatory framework for hemp-derived products.

Management Comments

• "Pleased with our third quarter 2025 results, highlighted by healthy gross margins of 48% and continued progress toward profitability and positive cash flow."
• "Our focus on organic growth through new product development, combined with strategic M&A opportunities, positions us to enhance top-line revenue and shareholder value."
• "Throughout 2025, our execution has been cost-efficient, and our commitment to innovation will diversify our product portfolio and help navigate the evolving regulatory landscape in the CBD category."
• "We look forward to building a more balanced portfolio that drives sustainable growth and profitability."
• "The funding legislation to reopen the federal government enacted yesterday that included restrictive language for the hemp industry is disappointing."
• "The restrictive hemp language will not go into effect for a one-year period from today."
• "CV Sciences will have an opportunity, along with other industry participants, to work on a bipartisan basis with members of Congress to shape a balanced and responsible regulatory framework that preserves access to hemp-derived, health and wellness products relied on by millions of consumers across the United States."

Industry Context

The company operates within the consumer wellness industry, specializing in hemp extracts and other natural ingredients. It faces an evolving regulatory landscape in the CBD category, highlighted by new federal funding legislation containing restrictive language for the hemp industry. This regulatory uncertainty is a significant factor for all players in the hemp-derived product market. CV Sciences positions itself as a preeminent company with a top-selling hemp-extract brand (+PlusCBD) in the natural products market, according to SPINS data.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess performance against global benchmarks. The analysis is primarily based on internal period-over-period comparisons.

Stakeholder Impact

• Shareholders: Face declining revenue and widening adjusted EBITDA losses, potentially impacting stock performance, but also benefit from improved gross margins and strategic efforts to diversify and address regulatory challenges.
• Customers: Benefit from new product offerings like 'Ignite' and the company's commitment to preserving access to hemp-derived health and wellness products.
• Employees: Operations continue with a focus on cost-efficiency and innovation, suggesting stability in the near term despite financial headwinds.
• Suppliers: May experience reduced demand due to lower sales volume and out-of-stock issues, but new product development could create new opportunities.
• Creditors: The declining cash balance and ongoing losses could raise concerns about the company's liquidity and ability to service debt, although net loss improved.

Next Steps

• Work on a bipartisan basis with members of Congress and other industry participants to shape a balanced and responsible regulatory framework for the hemp industry.
• Continue organic growth through new product development, such as the recently launched 'Ignite' men's performance formula.
• Pursue strategic M&A opportunities to enhance top-line revenue and shareholder value.
• Host a conference call and webcast on November 13, 2025, to discuss the financial results.

Key Dates

Recommendation

The company faces significant headwinds including a 16% revenue decline and a widening adjusted EBITDA loss, which are concerning. However, there are some positive indicators such as an improved gross margin year-over-year and a narrowed net loss. The one-year delay in the implementation of restrictive federal hemp legislation provides a crucial window for the company to lobby for a more favorable regulatory environment and adapt its strategy. Management's focus on new product development and potential M&A offers a path for future growth. Given the mixed financial performance, the strategic efforts, and the temporary regulatory reprieve, a 'hold' recommendation is appropriate as investors await clearer signs of a turnaround or further deterioration.

Keywords

CV Sciences, CVSI, Q3 2025 results, financial performance, hemp extracts, CBD, nutraceuticals, consumer wellness, regulatory landscape, adjusted EBITDA, gross margin, revenue, PlusCBD